Exicure, Inc. (XCUR)

Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for immuno-oncology, genetic disorders, and other indications. Its three clinical programs include AST-008, which is in a Phase I clinical trial, an SNA consisting of toll-like receptor 9 that is designed for immuno-oncology applications; XCUR17, which is in a Phase I clinical trial, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha, a protein that helps in the initiation and maintenance of psoriasis; and AST-005, which is in a Phase I clinical trial, an SNA that targets TNF for the treatment of mild to moderate psoriasis. Exicure, Inc. has collaboration agreements with Allergan plc; DERMELIX, LLC; and Purdue Pharma L.P. The company was founded in 2011 and is headquartered in Skokie, Illinois.

Current Quote*
Last: $2.645
Change: -0.035
Book: $2.723
Volume: 30,389

As Of: 05/29 12:50 ET
*Quotes delayed by 20min.

Graphs for XCUR


3 Month Graph


6 Month Graph


1 Year Graph